Human Embryonic Stem Cell miRNA Isolation for Regulatory Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human embryonic stem cells pose technical difficulties in cell culture and maintenance due to laborious procedures and longer population-doubling times compared to mouse embryonic stem cells, with limited understanding of their regulatory mechanisms, particularly regarding miRNA involvement.
Innovation Solution
Isolation and identification of novel miRNA molecules from human embryonic stem cells, including specific sequences and their precursors, which can be used for diagnostic and therapeutic applications, and as markers for stem cell identification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If human embryonic stem cells are used for research and therapy, then their unlimited self-renewal and differentiation capacity provide great potential, but technical difficulties in cell culture and laborious maintenance procedures hinder their utilization
Solution Approach 1:
The patent extracts and identifies specific miRNA molecules (miR-302b, miR-302c, miR-302a, miR-302d, miR-367, miR-200c, miR-368, miR-154, miR-369, miR-370, miR-371, miR-372, miR-373) from human embryonic stem cells, separating these regulatory molecules from the complex cellular environment. This extraction enables study and application of stem cell regulation without requiring continuous maintenance of the entire stem cell population, thus resolving the contradiction between their versatile capabilities and the difficulty of their cultural maintenance.
2Stability of the object's composition
If human embryonic stem cells are cultured, then they can be maintained under defined conditions, but their population-doubling time is almost three times longer than mouse embryonic stem cells, reducing productivity
Solution Approach 1:
The patent identifies miRNA molecules that are already present and functional in human embryonic stem cells, performing the regulatory action beforehand. By pre-identifying these miRNAs (miR-302b, miR-302c, miR-302a, miR-302d, miR-367, etc.), the patent enables better control and understanding of stem cell self-renewal mechanisms, which can indirectly influence cell proliferation rates and maintenance stability without requiring continuous lengthy culture periods.
3Loss of information
If regulatory mechanisms of human embryonic stem cells are studied, then understanding self-renewal and differentiation is enhanced, but only a few regulators like Oct4 are known, with limited information compared to mouse models
Solution Approach 1:
The patent segments the regulatory mechanism into specific, identifiable miRNA molecules (miR-302b, miR-302c, miR-302a, miR-302d, miR-367, miR-200c, miR-368, miR-154, miR-369, miR-370, miR-371, miR-372, miR-373) that can be individually studied and characterized. This segmentation transforms the complex, poorly understood regulatory network into discrete, manageable components, enabling systematic investigation of each miRNA's function in self-renewal and differentiation, thereby reducing the complexity barrier to understanding human stem cell regulation.
Data Source
AI summary
The present invention relates to novel miRNA molecules, more particularly to novel miRNA molecules isolated from human embryonic stem cells. The miRNA molecules provided by the present invention can be usefully used as a molecular marker for early developmental stages of undifferentiated human embryonic stem cells. Also, the miRNA molecules of the present invention may play an important role in the regulation of mammalian embryonic stem cells. Therefore, the miRNA molecules can be usefully used for analyzing regulatory networks of human embryonic stem cells.